Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
← CataloguePlate XVI of 81
XVIPlate XVIReviewed 2026-04-27

Cortagen

Bioregulatory Tetrapeptide

also known as Ala-Glu-Asp-Pro, AEDP

Synthetic tetrapeptide (Ala-Glu-Asp-Pro) derived from brain cortex peptide analysis in the Khavinson bioregulator tradition. Animal models demonstrate antioxidant activity, reduction of lipid peroxidation products and oxidative protein modification in rat serum and cerebral cortex. Distinguished from epithalon by terminal proline substitution; shows divergent biological activity profile in avian hypophysectomy models.

§ I

At a glance

Structure
Tetrapeptide
Antioxidant effect
↓ LPO products
Evidence level
Animal
Route

Injectable · Animal models

§ II

Mechanism

Edit ↗

Primary target — Cerebral cortex tissue — molecular targets under investigation.

Pathway — Antioxidant pathway modulation — suppression of LPO cascade, reduction of protein oxidative modification [kozina-2007].

Downstream effect — Decreased lipid peroxidation products, reduced oxidative protein damage, altered gene expression in cardiac tissue [kozina-2007][anisimov-2004].

Origin — Synthetic tetrapeptide derived from amino acid analysis of natural brain cortex peptide preparation Cortexin [anisimov-2004].

§ III

Dosage

Protocols described in the cited literature; not medical advice.

Edit ↗
ParameterValue
Animal model dose (rat)Injection protocol (dose not specified in abstracts)Multiple injections over study period.
Avian model dose (chicken)40-day injection course [kuznik-2008]Compared to epithalon in hypophysectomized and aged birds.
Human peripheral nerve studyTherapeutic course (protocol details not provided)Posttraumatic recovery context — reference cited but not detailed.
Evidence basisAnimal mechanistic studies
RouteInjectable (inferred from animal protocols)
§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs
mg
mL
mcg
The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to Cortagen's cited literature for protocol specifics.
Volumetric outputFig. C — reconstitution math
Volume per dose
0.100mL
10.0 units on a U-100 insulin syringe
Concentration
2500
mcg per mL
Doses per vial
20
at this dose

Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.

§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Edit ↗
Antioxidant suppressionmild
Suppression of antioxidant activity noted alongside LPO reduction [kozina-2007]
Immune/hemostasis effectsmild
No effect on immunity or hemostasis parameters in avian hypophysectomy model (unlike epithalon) [kuznik-2008]
Human safety data
No adverse events reported in peripheral nerve recovery context
§ VI

Administration

Edit ↗
  1. 01
    Preparation

    Reconstitute lyophilised peptide with bacteriostatic water per supplier protocol. Exact volumes depend on concentration supplied.

  2. 02
    Injection site

    Subcutaneous injection typical for bioregulatory peptides — abdomen or thigh. Rotate sites.

  3. 03
    Timing

    Animal protocols used repeated dosing over weeks. Human timing not established — evening administration common in Khavinson tradition.

  4. 04
    Storage

    Lyophilised: refrigerate or freeze per supplier. Reconstituted: refrigerate 2–8 °C, use within guideline window.

Appendix

Sources

31%

of 35 rendered claims carry a resolvable citation.

  1. [anisimov-2004]
    Anisimov 2004Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray.
    journal, 2004
  2. [kozina-2007]
    Kozina 2007Effects of bioactive tetrapeptides on free-radical processes.
    journal, 2007
  3. [kuznik-2008]
    Kuznik 2008[Effects of epithalon and cortagene on immunity and hemostasis in neonatally hypophysectomized chicken and old birds].
    journal, 2008
Plate composed 2026-04-27 · maturity human-reviewed · schema v1 · Contributors: peptidesdb-core · 24 fields uncited — open contributions